Age group differences in HIV outcomes, substance use and patient-reported health concerns among people with HIV enrolled in a primary-care based alcohol treatment study

Michael J. Silverberg, Varada Sarovar, Wendy A. Leyden, Jennifer O. Lam, J. Carlo Hojilla, Charles B. Hare, Michael A. Horberg, Derek D. Satre

Division of Research, Kaiser Permanente Northern California
University of California, San Francisco

Funding: NIAAA U01AA021997, K24AA025703




Aging-Related Challenges in HIV Care

- In spite of effective antiretroviral therapy (ART), concerns include:
 - Increasing physical and mental health comorbidity
 - Cognitive changes with age
 - Frailty
 - Polypharmacy
 - Effects of alcohol and other drug use



HIV and Life Expectancy at Age 20



Decreasing mortality rates (lines) and increasing life expectancy (dots) for HIV+, while stable for HIV-. However, a gap in life expectancy remains (13 years overall, or 8 years in well-treated HIV).



Impact of Unhealthy Alcohol Use among People with HIV (PWH)

- Cardiovascular disease
- Cognitive dysfunction
- Liver disease
- Cancer
- Infections
- Depression and anxiety
- Poor ART adherence
- Accelerated HIV disease progression

Williams et al., *ACER*, 2016 Oct; 40(10): 2056–2072; Azar et al., *Drug Alcohol Depend*. 2010;112(3):178-193; Samet et al., *J Acquir Immune Defic Syndr*. 2007;46(2):194-199.



Health & Motivation Intervention Study

- PWH in KP San Francisco primary care reporting ≥1 unhealthy drinking days in prior year
- 614 recruited by phone and randomized to three behavioral intervention conditions:
 - Motivational interviewing, emailed feedback, or usual care alone (SBIRT)
- Telephone follow up interviews at 6, 12 and 24 months
- All three groups improved by 12 months, no overall differences (MI was better for those with low motivation or drug use)
- 90% follow up rate at 24 months (N=553)



Current Analysis: 24-month Outcomes by Age

- Compared three age groups:
 - **–** 18-44, 45-54, 55+
- 30-day unhealthy drinking (4+/5+in a day for women/men),
- Other substance use
- Depression (PHQ-9) and anxiety (GAD-7)
- Quality of life (SF-12), pain, and clinical symptoms (checklist)
- Self-reported ART adherence
- EHR data:
 - HIV RNA and CD4 levels
 - Service utilization

Baseline Characteristics by Age Group

Characteristics	Total N = 553				
		18-44 N = 169	45-54 N =211	≥55 N = 173	P-value
	N (%)	%	%	%	
Male	537 (97.1)	95.9	96.7	98.8	0.23
Race/ethnicity					<.01
Black	52 (9.4)	7.7	12.3	7.5	
Hispanic	76 (13.7)	21.3	13.3	6.9	
Other/Unknown	72 (13.0)	21.3	12.8	5.2	
White	353 (63.8)	49.7	61.6	80.4	
Income					0.09
≥\$50K	336 (60.8)	53.8	67.3	59.5	
<\$50K	199 (36.0)	43.2	29.9	36.4	
Unknown	18 (3.3)	3.0	2.8	4.1	
≥1 unhealthy drinking days in prior 30 days	269 (48.6)	109 (64.5)	105 (49.8)	55 (31.8)	<.01

24-Month Substance Use, Health and HIV Outcomes

	Total				
Characteristics	Total N = 553	18-44 N = 169	45-54 N =211	≥55 N = 173	P-value
	N (%)	%	%	%	
30-day Substance Use					
Tobacco use	106 (19.2)	31.4	14.7	12.7	<.01
Marijuana use	261 (47.2)	47.9	43.1	51.5	0.26
Other substance use	112 (20.3)	29.0	17.1	15.6	<.01
Alcohol use	482 (87.2)	87.6	85.8	88.4	0.73
≥1 days of unhealthy drinking	133 (24.1)	37.9	23.7	11.0	<.01
Mental health / QOL					
Moderate/severe anxiety	66 (11.9)	14.2	12.3	9.3	0.13
Moderate/severe depression	66 (11.9)	11.8	12.3	11.6	0.97
Mental quality of life+	Mean (SD) = 48.9 (9.9)	47.5 (10.9)	48.3 (11.0)	49.3 (10.7)	0.33
Physical quality of life+	Mean (SD) = 48.4 (10.9)	52.2 (7.3)	48.9 (10.1)	46.1 (10.7)	<.01
HIV Outcomes					
ART adherence ≥ 95%++	427 (82.3)	79.4	83.0	84.2	0.50
HIV RNA < 75 copies/mL	517 (93.5)	90.5	94.8	94.8	0.17
CD4 T-cells/µl	Mean (SD) = 703.5 (287.4)	724.2 (281.3)	731.9 (279.5)	648.8 (296.6)	<.01

⁺³⁸ PWH with missing both physical and mental quality of life information. ++34 PWH with missing ART adherence information .

Pain Level at 24 Months

	Total N = 553	1			
Pain measure		18-44 N = 169	45-54 N =211	≥55 N = 173	P-value
	N (%)	%	%	%	
Moderate / Severe bodily pain in the past 4 weeks ¹					<.01
Yes	153 (27.7)	18.3	32.7	30.6	
No	400 (72.3)	81.7	67.3	69.4	
Pain interferes with normal work ²					<.01
Yes	235 (42.5)	32.5	43.1	51.5	
No	280 (50.6)	53.9	50.7	47.4	
Not applicable	38 (6.9)	13.6	6.2	1.2	

¹ Yes = Moderate + Severe + very severe; No = None + very mild + Mild. ² Yes = A little bit + Moderately +Quite a bit + Extremely; No = Not at all

Symptom Checklist by Age Group at 24 Months

Characteristics	Total N = 553				
		18-44 N = 169	45-54 N =211	≥55 N = 173	P-value
	N (%)	%	%	%	
Any symptoms					0.02
Yes	76 (13.7)	81.7	85.3	91.9	
No	477 (86.3)	18.3	14.7	8.1	
Total symptoms					0.15
0	76 (13.7)	18.3	14.7	8.1	
1 - 4	176 (31.8)	32.0	31.3	32.4	
5 - 9	171 (30.9)	29.6	31.8	31.2	
10 - 14	106 (19.2)	17.2	16.6	24.3	
15 - 19	24 (4.3)	3.0	5.7	4.1	

Summary of total symptoms: Minimum (Maximum) = 0 (19); Mean (SD) = 5.8 (4.6), Median = 5.0

Prior-Year Service Utilization by Age Group at 24 Months

Characteristics	Total N = 553				
		18-44 N = 169	45-54 N =211	≥55 N = 173	P-value
	N (%)	%	%	%	
Utilization					
Any utilization	488 (88.3)	79.9	90.1	94.2	<.01
Primary Care	371 (67.1)	53.3	72.0	74.6	<.01
Mental health	56 (10.1)	7.1	10.4	12.7	0.22
Addiction Medicine	24 (4.3)	5.3	4.3	3.5	0.70
Other Ambulatory	235 (42.5)	30.2	45.0	51.5	<.01
Emergency	39 (7.1)	4.7	7.1	9.3	0.26
Inpatient	8 (1.5)	0.6	2.4	1.2	0.36

⁺ P-value based on Fisher's exact test

Age Effects on 24-month Mental Health and Quality of Life Outcomes

Outcomes	Age (years)	Unadjusted Model		Adjusted Model	
		OR (95% CI)	P-value	OR (95% CI)	P-value
Moderate/severe anxiety	18-44	1.62 (0.83 ,3.19)	0.1572	1.89 (0.90 ,3.95)	0.09
	45-54	1.38 (0.71 ,2.66)	0.3389	1.47 (0.74 ,2.94)	0.27
	≥55	Reference	Reference	Reference	Reference
Moderate/severe depression	18-44	1.03 (0.53 ,1.99)	0.9373	1.08 (0.52 ,2.25)	0.83
	45-54	1.08 (0.58 ,2.00)	0.8192	1.15 (0.6 ,2.22)	0.67
	≥55	Reference	Reference	Reference	Reference
		β (SE)	P-value	β (SE)	P-value
Mental quality of life	18-44	-1.80 (1.22)	0.1411	-1.64 (1.29)	0.20
	45-54	-1.02 (1.13)	0.3685	-1.21 (1.14)	0.29
	≥55	Reference	Reference	Reference	Reference
Physical quality of life	18-44	6.14 (1.08)	<.0001	6.12 (1.15)	<.01
	45-54	2.85 (1.00)	0.0047	2.96 (1.02)	<.01
	≥55	Reference	Reference	Reference	Reference

Covariates: sex, Race/ethnicity, education, Married, social support, unhealthy alcohol drinking, tobacco smoking.

24-Month HIV Outcomes by Age Group

Outcomes	Age (years)	Unadjusted Model		Adjusted Model	
		OR (95% CI)	P-value	OR (95% CI)	P-value
ART adherence ≥ 95%	18-44	0.72 (0.41 ,1.28)	0.2685	1.03 (0.54 ,1.95)	0.94
	45-54	0.92 (0.53 ,1.61)	0.7694	1.03 (0.57 ,1.85)	0.93
	≥55	Reference	Reference	Reference	Reference
HIV RNA < 75 copies/mL	18-44	0.53 (0.23 ,1.22)	0.1351	0.51 (0.2 ,1.34)	0.17
	45-54	1.00 (0.40 ,2.47)	0.9962	1.04 (0.39 ,2.75)	0.94
	≥55	Reference	Reference	Reference	Reference
		β (SE)	P-value	β (SE)	P-value
CD4 T-cells/µl	18-44	75.41 (30.88)	0.0149	64.47 (33.48)	0.05
	45-54	83.17 (29.28)	0.0047	83.53 (30.04)	<.01
	≥55	Reference	Reference	Reference	Reference

Covariates sex (male, female[reference]), age (18-44, 45-54, ≥55 [reference]), Race/ethnicity (Black, Hispanic, Other, White [reference]), education (graduate, some college/college, ≤ HS [reference]), Married (yes, no[reference]), social support, unhealthy alcohol drinking (yes, no[reference]), tobacco smoking (yes, no[reference]).

Limitations

- Participants were drawn from a single clinic in San Francisco
- Enrolled in an alcohol intervention study
- Privately insured
- Mostly MSM

Summary & Clinical Implications

- In a sample of PWH with good viral control and a history of unhealthy alcohol use:
 - Older adults report less unhealthy drinking than younger PWH
 - High levels of alcohol and cannabis use regardless of age
 - Lower CD4 count, indicating worse immune function
 - But trend for younger adults to have worse viral suppression
 - Pain and physical health problems are higher in older adults
 - Higher outpatient service utilization
- Understanding age-associated differences can assist in planning effective health services for PWH as this population ages
- Further analyses will examine the relationship of alcohol and cannabis use to pain, medical problems and quality of life

Drug and Alcohol / HIV Collaborators at Kaiser Permanente Northern California Division of Research

Principal Investigators

Cynthia Campbell, PhD
Derek Satre, PhD
Michael Silverberg, PhD, MPH
Stacy Sterling, DrPH
Connie Weisner, DrPH, LCSW
Kelly Young-Wolff, PhD, MPH

Health Economist

Sujaya Parthasarathy, PhD

Senior Research Administrator

Alison Truman, MA

Analysts/Biostaticians

Felicia Chi, MPH
Andrea H Kline-Simon, MS
Wendy Lu, MPH
Tom Ray, MBA
Wendy Leyden, MPH
Leo Hurley, MPH

Postdoctoral Fellows

Carlo Hojilla, PhD Jennifer Lam, PhD Esti Iturralde, PhD

Interview Supervisor

Gina Smith Anderson

Project Coordinators

Agatha Hinman, BA Kathleen Haley, MFT Monique Does

Research Associates

Georgina Berrios Diane Lott-Garcia Melanie Jackson

Barbara Pichotto KPNC Members
Lynda Tish KPNC Primary Care

KPNC Regional HIV Advisory Committee

KPNC Adolescent Medicine Specialists Committee

KPNC Adolescent Chemical Dependency Coordinating Committee KPNC Oakland Pediatrics Department

KPNC Regional Mental Health and Chemical Dependency

Research Clinicians

Amy Leibowitz, PsyD Thekla B Ross, PsyD Ashley Jones, PsyD

Clinical Partners

Linda Kim, MD
Brad Hare, MD
Jason Flamm, MD
Sally Slome, MD
Charles Moore, MD, MBA
Don Mordecai, MD
Murtuza Ghadiali, MD

